Biotech companies in Massachusetts continue to gain investments amid a declining stock market and dwindling initial public offerings. Agios Pharmaceuticals, a Boston-based firm working on drugs designed to starve cancerous cells, has secured $33 million in venture capital. Concert Pharmaceuticals and Constellation Pharmaceuticals also each have raised more than $30 million this year.

Related Summaries